TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
TC BioPharm (TCBP) has announced a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company through an all-stock transaction. The target company has an FDA-approved once-daily eye drop for treating glaucoma and ocular hypertension, currently being distributed to 300 physicians for sample treatments.
The acquisition aligns with TCBP's M&A strategy to expand its therapeutic platform and incorporate later-stage assets. The target company's product is expected to generate meaningful revenue in 2025, targeting a market projected to exceed $8 billion in a single patient population. TCBP anticipates executing the binding letter of intent within 2-3 weeks and closing the acquisition in Q3 2025.
The global glaucoma market, valued at $8.06 billion in 2022, is projected to reach $12.69 billion by 2032. This acquisition represents TCBP's transformation from a focused developer to a diversified therapeutics company.
TC BioPharm (TCBP) ha annunciato una lettera di intenti non vincolante per acquisire un'azienda farmaceutica oftalmica in fase commerciale tramite una transazione interamente azionaria. L'azienda target possiede un collirio approvato dalla FDA da somministrare una volta al giorno per il trattamento del glaucoma e dell'ipertensione oculare, attualmente distribuito a 300 medici per trattamenti dimostrativi.
L'acquisizione si allinea con la strategia di M&A di TCBP per espandere la propria piattaforma terapeutica e incorporare asset in fasi più avanzate. Si prevede che il prodotto dell'azienda target genererà ricavi significativi nel 2025, mirando a un mercato che si prevede supererà 8 miliardi di dollari in una singola popolazione di pazienti. TCBP prevede di eseguire la lettera di intenti vincolante entro 2-3 settimane e di chiudere l'acquisizione nel terzo trimestre del 2025.
Il mercato globale del glaucoma, valutato 8,06 miliardi di dollari nel 2022, è previsto raggiungere 12,69 miliardi di dollari entro il 2032. Questa acquisizione rappresenta la trasformazione di TCBP da sviluppatore focalizzato a azienda terapeutica diversificata.
TC BioPharm (TCBP) ha anunciado una carta de intención no vinculante para adquirir una empresa farmacéutica oftálmica en etapa comercial a través de una transacción totalmente en acciones. La empresa objetivo cuenta con un colirio aprobado por la FDA para uso diario para tratar el glaucoma y la hipertensión ocular, que actualmente se distribuye a 300 médicos para tratamientos de muestra.
La adquisición se alinea con la estrategia de M&A de TCBP para expandir su plataforma terapéutica e incorporar activos en etapas más avanzadas. Se espera que el producto de la empresa objetivo genere ingresos significativos en 2025, apuntando a un mercado proyectado para superar 8 mil millones de dólares en una sola población de pacientes. TCBP anticipa ejecutar la carta de intención vinculante en un plazo de 2-3 semanas y cerrar la adquisición en el tercer trimestre de 2025.
El mercado global del glaucoma, valorado en 8,06 mil millones de dólares en 2022, se proyecta que alcanzará 12,69 mil millones de dólares para 2032. Esta adquisición representa la transformación de TCBP de un desarrollador enfocado a una empresa terapéutica diversificada.
TC BioPharm (TCBP)는 상장된 안과 제약 회사를 전액 주식 거래를 통해 인수하기 위한 비구속적 의향서를 발표했습니다. 목표 회사는 FDA 승인 일일 점안액을 보유하고 있으며, 현재 300명의 의사에게 샘플 치료를 위해 배포되고 있습니다.
이번 인수는 TCBP의 M&A 전략과 일치하여 치료 플랫폼을 확장하고 후속 단계 자산을 통합하는 것을 목표로 하고 있습니다. 목표 회사의 제품은 2025년에 상당한 수익을 창출할 것으로 예상되며, 단일 환자 집단에서 80억 달러를 초과할 것으로 예상되는 시장을 목표로 하고 있습니다. TCBP는 2-3주 이내에 구속력 있는 의향서를 실행하고 2025년 3분기에 인수를 마무리할 계획입니다.
2022년 80억 6천만 달러로 평가된 글로벌 녹내장 시장은 2032년까지 126억 9천만 달러에 이를 것으로 예상됩니다. 이번 인수는 TCBP가 집중 개발자에서 다각화된 치료 회사로 변모하는 것을 의미합니다.
TC BioPharm (TCBP) a annoncé une lettre d'intention non contraignante pour acquérir une entreprise pharmaceutique ophtalmique en phase commerciale par le biais d'une transaction entièrement en actions. L'entreprise cible dispose d'un collyre approuvé par la FDA à administrer une fois par jour pour traiter le glaucome et l'hypertension oculaire, actuellement distribué à 300 médecins pour des traitements d'échantillon.
L'acquisition s'inscrit dans la stratégie de M&A de TCBP visant à élargir sa plateforme thérapeutique et à intégrer des actifs à un stade ultérieur. Le produit de l'entreprise cible devrait générer des revenus significatifs en 2025, visant un marché projeté à dépasser 8 milliards de dollars pour une seule population de patients. TCBP prévoit d'exécuter la lettre d'intention contraignante dans un délai de 2 à 3 semaines et de finaliser l'acquisition au troisième trimestre 2025.
Le marché mondial du glaucome, évalué à 8,06 milliards de dollars en 2022, devrait atteindre 12,69 milliards de dollars d'ici 2032. Cette acquisition représente la transformation de TCBP d'un développeur concentré à une entreprise thérapeutique diversifiée.
TC BioPharm (TCBP) hat einen nicht verbindlichen Letter of Intent angekündigt, um ein kommerziell tätiges ophthalmologisches Pharmaunternehmen durch eine vollständig aktienbasierte Transaktion zu erwerben. Das Zielunternehmen verfügt über einen von der FDA genehmigten, einmal täglich anzuwendenden Augentropfen zur Behandlung von Glaukom und okulärer Hypertonie, der derzeit an 300 Ärzte zur Probenbehandlung verteilt wird.
Die Übernahme entspricht der M&A-Strategie von TCBP, die therapeutische Plattform zu erweitern und späteren Entwicklungsstadien Vermögenswerte einzugliedern. Es wird erwartet, dass das Produkt des Zielunternehmens im Jahr 2025 signifikante Einnahmen generieren wird und einen Markt anvisiert, der voraussichtlich 8 Milliarden Dollar in einer einzigen Patientengruppe übersteigen wird. TCBP plant, den verbindlichen Letter of Intent innerhalb von 2-3 Wochen umzusetzen und die Übernahme im 3. Quartal 2025 abzuschließen.
Der globale Glaukommarkt, der 2022 mit 8,06 Milliarden Dollar bewertet wurde, wird voraussichtlich bis 2032 12,69 Milliarden Dollar erreichen. Diese Übernahme stellt die Transformation von TCBP von einem fokussierten Entwickler zu einem diversifizierten Therapeutikunternehmen dar.
- FDA-approved product ready for commercialization
- Access to $8+ billion market opportunity
- Revenue generation expected in 2025
- Pipeline of development stage assets in ophthalmology
- Experienced management team from target company
- Strategic diversification beyond current focus
- All-stock transaction may lead to shareholder dilution
- Non-binding LOI carries execution risk
- No immediate revenue impact
- Integration risks with new therapeutic area
Insights
TCBP's letter of intent to acquire a commercial-stage ophthalmic company represents a transformative strategic shift from a clinical-stage biotech focused solely on gamma-delta T cell therapies to a diversified company with near-term revenue potential. The acquisition target brings three significant assets: an FDA-approved once-daily eye drop for intraocular pressure, a development pipeline in ophthalmology, and an experienced management team.
The most immediate value driver is the FDA-approved product already being sampled to 300 physicians, with commercial launch imminent and revenue generation expected in 2025. This accelerates TCBP's timeline to commercialization substantially, as the company's own pipeline remains in clinical development.
The all-stock transaction structure preserves cash but will cause dilution for existing shareholders. However, entering the $8.06 billion glaucoma market provides significant diversification and reduces TCBP's risk profile by decreasing reliance on clinical trial outcomes for their gamma-delta T cell platform.
Management's projection of "hyper revenue growth" and an $8 billion market for their drop in a single patient population suggests substantial revenue potential if execution is successful. The ophthalmology sector has seen $10+ billion in M&A activity over the past 18 months, indicating strong industry interest and potential exit opportunities.
While this remains a non-binding agreement with closure projected for Q3 2025, this represents a significant potential value inflection point for what has been a small-cap biotech company.
TCBP's strategic move into ophthalmology through this acquisition represents calculated portfolio diversification that significantly de-risks their business model. Moving from a single-platform, clinical-stage biotech into commercial-stage operations fundamentally changes their investment profile and potential valuation metrics.
The glaucoma market presents compelling dynamics with its $8.06 billion current size and projected growth to $12.69 billion by 2032. Current treatments face challenges with side effects and patient adherence, creating market opportunity for improved therapies. The acquired company's once-daily dosing could drive adoption by addressing the adherence issues common with glaucoma medications requiring multiple daily applications.
The acquisition's structure as an all-stock transaction preserves TCBP's capital while allowing for immediate expansion into a commercial therapeutic area. This approach balances growth against financial constraints typical of small biotech companies.
While the sampling program to 300 physicians shows initial commercialization efforts are underway, the critical metrics to watch will be physician adoption rates, insurance coverage decisions, and patient conversion from existing treatments. The company's projection of "meaningful revenue in 2025" suggests confidence in their commercialization timeline, though the exact revenue trajectory remains uncertain.
This acquisition aligns with industry trends showing increased interest in ophthalmology assets, with $10 billion in M&A and funding directed to the sector recently. The strategy creates multiple potential value creation pathways - organic growth, further acquisitions, or positioning for acquisition by larger pharmaceutical companies interested in ophthalmology assets.
- FDA-approved product in a multi-billion-dollar market
- Revenue generation projected in 2025
The acquisition candidate has an FDA-approved once-per-day drop to decrease intraocular pressure, a pipeline of development stage assets in ophthalmology indications, and is led by a seasoned management team. Currently, the approved product is being shipped to 300 physicians for a three-month treatment sample. A commercial launch will follow in the coming months, generating meaningful revenue in 2025.
Under the terms and conditions of the agreement, TC BioPharm will acquire
"With this agreement, TCBP will rapidly accelerate its strategic trajectory from a singularly focused developer to a diversified therapeutics company," said Bryan Kobel, Chief Executive Officer of TC BioPharm. "This target candidate's management team has extensive experience in multiple pharma and drug development success stories and is projecting hyper revenue growth over the coming 24 months with a market projection for their drop to be over
The global glaucoma market size was estimated at
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
Forward-Looking Statements for TC BioPharm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-announces-non-binding-letter-of-intent-to-acquire-commercial-stage-ophthalmic-pharmaceutical-company-302393099.html
SOURCE TC BioPharm
FAQ
What is the expected timeline for TCBP's acquisition completion of the ophthalmic pharmaceutical company?
How many physicians are currently receiving sample treatments of TCBP's newly acquired eye drop product?
What is the projected market size for TCBP's newly acquired glaucoma eye drop product?
What is the global glaucoma market size projection by 2032 relevant to TCBP's acquisition?
When does TCBP expect to generate revenue from the newly acquired ophthalmic product?
